Tonix Pharmaceuticals Holding Corp. insider trading

Every open-market purchase and sale by Tonix Pharmaceuticals Holding Corp.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $458,758 7 trades by 4 insiders 3 months later: median +4.6% (+1.3% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Tonix Pharmaceuticals Holding Corp. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Tonix Pharmaceuticals Holding Corp.’s insiders pay?

From May 5, 2011 to August 31, 2026, 11 insiders reported 64 open-market purchases and 2 sales not made under a pre-set plan in Tonix Pharmaceuticals Holding Corp. Twelve months after each purchase was reported, the shares were −70.9% against the S&P 500 on average (median −73.1%), over 23 purchases with a full year of prices; 0% beat the index. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on February 10, 2015 into $267 by November 2, 2026, −26.6% a year. It held shares 27% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $17,032 (+4.7% a year), and held throughout $44,393 (+13.6%).

Copying Tonix Pharmaceuticals Holding Corp.'s insidersS&P 500, same days investedS&P 500, held throughout $10,000 copying every open-market purchase by Tonix Pharmaceuticals Holding Corp.'s insiders from February 10, 2015, before costs and taxes, marked weekly. Uninvested money earns the Treasury bill rate; the portfolio held shares 27% of the time.

Tonix Pharmaceuticals Holding Corp.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Lederman Seth	Chief Executive Officer	32	−68.2% (9)	0%	0	—	August 31, 2026
Mario Ernest	Director	14	−66.2% (7)	0%	2	—	June 27, 2018
Sullivan Gregory M	Chief Medical Officer	6	−93.3% (3)	0%	0	—	August 19, 2020
Rhodes John B	Director	3	−81.1% (1)	0%	0	—	June 6, 2018
Saks Samuel R	Director	2	−81.1% (1)	0%	0	—	June 21, 2016
Taylor Carolyn E.	Director	2	−84.0% (1)	0%	0	—	June 15, 2026
Bagger Richard H	Director	1	—	—	0	—	August 24, 2026
Daugherty Bruce	See remarks	1	—	—	0	—	June 21, 2016
Gershell Leland	Chief Financial Officer	1	−26.3% (1)	0%	0	—	February 9, 2015
Moss David J	PRES, CEO, TRES, CFO, SECR	1	—	—	0	—	May 5, 2011
Stillwell Richard Newcomb	Director	1	—	—	0	—	June 9, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

When several insiders traded Tonix Pharmaceuticals Holding Corp.

Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Tonix Pharmaceuticals Holding Corp. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After the 2 buying crowds with six months of prices, it averaged −9.8% against the index. One company's history is too short to judge by; the test across every company is the better guide.

Month	Crowd	3 months on, vs S&P 500	6 months	12 months
June 30, 2026	3 buying	−27.0%	not yet	not yet
July 31, 2015	5 buying	−22.7%	−34.4%	−81.0%
February 27, 2015	3 buying	+21.2%	+14.9%	−52.1%

Colours show whether the crowd was right: green when buyers were followed by a rise above the index, or sellers by a fall below it. Total returns from the month end; past patterns are not a forecast.

← Back to Tonix Pharmaceuticals Holding Corp. · Funds · Politicians